Bio-Rad Human Metabolic and Hormone Assays - Manual (Page 3)

1
Introduction
Approximately 65% of individuals with diabetes die from heart disease
and stroke. Individuals with type 2 diabetes also have an increased rate of
high blood pressure, lipid problems, and obesity, which contribute to their
high rates of cardiovascular disease (CVD). Given the complexity of these
conditions, it is not surprising that assessment of a single biomarker alone has
not yielded more than an incremental advantage over traditional measures
of assessing risk. In diabetes, further complexity is added by the common
coincidence of metabolic syndrome, which includes insulin resistance,
dyslipidemia, hypertension, and systemic inflammation, all of which contribute
to the pathogenesis of CVD (Iqbal et al. 2012). As such, researchers studying
CVD and/or diabetes need to monitor multiple biomarkers for cardiovascular
risk factors along with biomarkers directly linked to the metabolic disorders
mentioned above. These markers include gut and pituitary hormones,
adipokines, growth factors, and cardiovascular and acute phase–related
proteins. Since these hormones and proteins frequently act in concert, it
is advantageous to have the capacity to measure a number of different
biomarkers simultaneously in a single blood sample.
Bio-Plex Pro
™
RBM Metabolic and Hormone Assays
The Bio-Plex Pro RBM metabolic and hormone assays include a wide
range of proteins implicated in the pathophysiology of diabetes, obesity,
and metabolic syndrome, as well as biomarkers for associated conditions
such as cardiovascular disease and inflammation.
For researchers working with limited sample volume, the capacity to
multiplex provides an effective option over the traditional ELISA method.
The use of magnetic (MagPlex) beads allows researchers to automate
wash steps on a Bio-Plex Pro (or similar) wash station.
References
Iqbal N et al. (2012). Cardiac biomarkers: New tools for heart failure
management. Cardiovas Diagn Ther 2, 147–164.